PharmaCyte Biotech, Inc. (PMCB) Balance Sheet
PMCB balance sheet, FY2026
April 30, 2026 · U.S. dollars$46.8M assets = $11.8M liabilities + $35.0M equity
Both columns are drawn to the same scale: what PMCB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PMCB financial health
Equity / assets71.2%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles0.0%
Mostly tangible · of total assets
Descriptive bands, not a rating. Fiscal FY2026.
PMCB balance sheet trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $8.7MFY2017 | $46.8MFY2026 | +20.6%/yr | |
| Total liabilities | $580,248FY2017 | $11.8MFY2026 | +39.7%/yr | |
| Shareholders’ equity | $8.1MFY2017 | $33.3MFY2026 | +17.0%/yr | |
| Cash & short-term investments | $3.5MFY2017 | $37.1MFY2026 | +30.1%/yr | |
| Total debt | $75,200FY2020 | $50,805FY2021 | −32.4%/yr | |
| Net cash (debt) | $2.4MFY2020 | $2.2MFY2021 | −$240,553 | |
| Working capital | $3.0MFY2017 | $36.6MFY2026 | +$33.6M | |
| Book value per share | $5.79FY2022 | $3.97FY2026 | −9.0%/yr | |
| Debt / equity | 0.01FY2020 | 0.01FY2021 | −0.01 | |
| Shares outstanding | 15.5MFY2022 | 8.4MFY2026 | −14.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PMCB assets
Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current
PMCB liabilities and equity
Current liabilitiesLong-term debtOther long-term liabilitiesEquity
PMCB debt vs cash
Total debtCash & ST investmentsNet cash (debt)
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PMCB balance sheet
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $37.1M | $15.5M | $50.2M | $68.0M | $85.4M | $2.2M | $2.5M | $515,253 | $1.1M | $3.5M |
| Cash & equivalents | $18.6M | $15.2M | $50.2M | $68.0M | $85.4M | $2.2M | $894,861 | $515,253 | $1.1M | $3.5M |
| Short-term investments | $18.5M | $366,316 | $0 | — | — | — | $1.6M | — | — | — |
| Receivables | $240,766 | $3.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $96,879 | $3.1M | $259,800 | $107,681 | $94,172 | $73,131 | $0 | $138,151 | $224,067 | $74,274 |
| Total current assets | $37.4M | $22.4M | $50.4M | $68.1M | $85.5M | $2.3M | $1.0M | $653,404 | $1.3M | $3.5M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $1.5M | $1.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M |
| Long-term investments | $0 | $22.5M | $0 | $1.6M | $1.6M | $1.6M | $1.6M | $1.6M | $1.6M | $1.6M |
| Other non-current assets | $9.3M | $8.8M | $7.9M | $7,688 | $7,688 | $7,372 | $7,372 | $7,372 | $7,372 | $7,372 |
| Total assets | $46.8M | $55.2M | $59.9M | $73.3M | $90.6M | $7.4M | $6.2M | $5.8M | $6.4M | $8.7M |
| Liabilities | ||||||||||
| Accounts payable | $271,102 | $399,204 | $389,369 | $128,281 | $205,361 | $172,261 | $185,842 | $121,885 | $352,621 | $365,600 |
| Short-term debt | — | — | — | — | — | $50,805 | $28,918 | — | — | — |
| Deferred revenue | — | — | — | — | — | −$50,805 | — | — | — | — |
| Total current liabilities | $826,424 | $2.9M | $7.4M | $586,581 | $704,370 | $724,778 | $1.0M | $742,851 | $644,168 | $580,248 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $46,282 | $0 | $0 | $0 |
| Other long-term liabilities | $9.3M | $363,000 | $13.0M | $0 | $205,361 | $172,261 | $0 | $121,885 | $0 | $0 |
| Total liabilities | $11.8M | $3.3M | $20.4M | $586,581 | $704,370 | $724,778 | $1.1M | $742,851 | $644,168 | $580,248 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $2,602 | $2,167 | $2,167 | $2,160 | $2,072 | $159 | $163,864 | $118,600 | $101,326 | $90,534 |
| Retained earnings (deficit) | −$104.4M | −$85.0M | −$115.6M | −$116.0M | −$111.6M | −$107.4M | −$103.9M | −$100.0M | −$96.0M | −$89.1M |
| Accumulated other comprehensive income | −$20,796 | −$23,869 | −$23,511 | −$23,003 | −$15,757 | −$20,382 | −$21,709 | −$13,842 | −$4,709 | $1,736 |
| Total shareholders' equity | $33.3M | $51.9M | $39.5M | $72.7M | $89.9M | $6.7M | $5.1M | $5.0M | $5.8M | $8.1M |
| Key figures | ||||||||||
| Total debt | — | — | — | — | — | $50,805 | $75,200 | — | — | — |
| Net cash (debt) | — | — | — | — | — | $2.2M | $2.4M | — | — | — |
| Working capital | $36.6M | $19.5M | $43.0M | $67.6M | $84.8M | $1.6M | $6,248 | −$89,447 | $639,697 | $3.0M |
| Tangible book value | $33.3M | $50.3M | $38.0M | $69.1M | $86.4M | $3.1M | $1.5M | $1.5M | $2.2M | $4.5M |
| Book value per share | $3.97 | $7.08 | $4.12 | $3.73 | $5.79 | — | — | — | — | — |
| Shares outstanding | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | — | — | — | — | — |
| Current ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 | 3.14 | 1.01 | 0.88 | 1.99 | 6.10 |
| Quick ratio | 45.16 | 6.60 | 6.76 | 115.99 | 121.24 | 3.04 | 2.39 | 0.69 | 1.65 | 5.97 |
| Debt / equity | — | — | — | — | — | 0.01 | 0.01 | — | — | — |
| Equity / assets | 71.2% | 94.1% | 66.0% | 99.2% | 99.2% | 90.2% | 82.5% | 87.2% | 90.0% | 93.3% |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $30.5M | $37.1M | $20.5M | $15.6M | $13.4M | $15.5M | $16.8M | $20.8M | $32.6M | $50.2M | $61.2M | $73.4M |
| Cash & equivalents | $17.7M | $18.6M | $20.2M | $15.4M | $13.2M | $15.2M | $16.4M | $20.8M | $32.6M | $50.2M | $61.2M | $73.4M |
| Short-term investments | $12.8M | $18.5M | $372,251 | $201,190 | $261,853 | $366,316 | $372,632 | — | — | $0 | — | — |
| Receivables | $429,150 | $240,766 | $0 | $5.0M | $4.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $32,004 | $96,879 | $158,664 | $2.4M | $1.1M | $6.8M | $207,362 | $493,213 | $240,227 | $259,800 | $297,762 | $323,189 |
| Total current assets | $31.0M | $37.4M | $20.7M | $23.0M | $19.1M | $22.4M | $17.0M | $21.3M | $32.9M | $50.4M | $61.5M | $73.7M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $3.5M | $3.5M |
| Long-term investments | $0 | $0 | $22.5M | $20.7M | $0 | $22.5M | $0 | $24.9M | $29.1M | $0 | $1.6M | $1.6M |
| Other non-current assets | $5.7M | $9.3M | $11.2M | $10.7M | $24.5M | $8.8M | $25.3M | $7.4M | $6.6M | $7.9M | $4.7M | $7,688 |
| Total assets | $36.7M | $46.8M | $55.9M | $56.0M | $45.1M | $55.2M | $43.8M | $55.1M | $70.2M | $59.9M | $71.4M | $78.9M |
| Liabilities | ||||||||||||
| Accounts payable | $390,535 | $271,102 | $1.2M | $1.0M | $465,209 | $399,204 | $484,948 | $348,595 | $553,952 | $389,369 | $484,198 | $126,163 |
| Total current liabilities | $768,682 | $826,424 | $1.7M | $1.6M | $1.1M | $2.9M | $1.2M | $4.8M | $7.5M | $7.4M | $7.5M | $5.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $6.1M | $9.3M | $14.8M | $17.8M | $458,000 | $363,000 | $2.4M | $6.9M | $9.7M | $13.0M | $14.9M | $15.6M |
| Total liabilities | $6.9M | $11.8M | $16.5M | $19.4M | $1.5M | $3.3M | $3.6M | $11.6M | $17.2M | $20.4M | $22.5M | $20.8M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $2,602 | $2,602 | $2,602 | $2,167 | $2,167 | — | $2,167 | $2,167 | $2,167 | — | $2,167 | $2,167 |
| Retained earnings (deficit) | −$109.5M | −$104.4M | −$100.0M | −$100.7M | −$93.3M | −$85.0M | −$96.7M | −$93.7M | −$92.2M | −$115.6M | −$117.0M | −$116.4M |
| Accumulated other comprehensive income | −$21,411 | −$20,796 | −$21,540 | −$24,127 | −$23,746 | — | −$24,486 | −$23,267 | −$23,328 | — | −$23,073 | −$24,143 |
| Total shareholders' equity | $29.8M | $33.3M | $39.4M | $36.6M | $43.6M | $51.9M | $40.3M | $43.5M | $53.0M | $39.5M | $48.9M | $58.1M |
| Key figures | ||||||||||||
| Working capital | $30.2M | $36.6M | $19.0M | $21.4M | $18.0M | $19.5M | $15.8M | $16.6M | $25.4M | $43.0M | $54.0M | $68.5M |
| Tangible book value | $29.8M | $33.3M | $37.9M | $35.0M | $42.0M | $50.3M | $38.7M | $41.9M | $51.5M | $38.0M | $45.3M | $54.5M |
| Book value per share | $2.78 | $3.12 | $4.25 | $5.38 | $6.41 | $7.64 | $5.78 | $5.69 | $6.74 | $4.92 | $5.68 | $6.62 |
| Shares outstanding | 10.7M | 10.7M | 9.3M | 6.8M | 6.8M | 6.8M | 7.0M | 7.6M | 7.9M | 8.0M | 8.6M | 8.8M |
| Current ratio | 40.30 | 45.28 | 12.33 | 14.60 | 18.01 | 7.68 | 14.20 | 4.47 | 4.40 | 6.80 | 8.16 | 14.08 |
| Quick ratio | 40.25 | 45.16 | 12.24 | 13.06 | 17.01 | 5.33 | 14.03 | 4.36 | 4.37 | 6.76 | 8.12 | 14.01 |
| Equity / assets | 81.2% | 71.2% | 70.5% | 65.3% | 96.6% | 94.1% | 91.8% | 78.9% | 75.6% | 66.0% | 68.5% | 73.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed July 29, 2026); data from EODHD.
PMCB financial position
At the end of fiscal 2026 (April 30, 2026), PharmaCyte Biotech had total assets of $46.8 million (down 15.3% from a year earlier), total liabilities of $11.8 million and shareholders' equity of $33.3 million. Its current ratio was 45.28. In the latest quarter (ended July 31, 2026) total assets were $36.7 million and equity $29.8 million.
Related: PMCB income statement, PMCB cash flow statement, PMCB key metrics. See the PMCB stock overview for the latest quote and news.
PMCB balance sheet FAQ
What are PharmaCyte Biotech's total assets?
PharmaCyte Biotech reported total assets of $46.8 million at the end of fiscal 2026 (April 30, 2026), compared with $55.2 million a year earlier.
How much cash does PharmaCyte Biotech have?
PharmaCyte Biotech held $37.1 million in cash and short-term investments at the end of fiscal 2026.
What is PharmaCyte Biotech's book value?
PharmaCyte Biotech's shareholders' equity (book value) was $33.3 million at the end of fiscal 2026, or $3.97 per share.
What is PharmaCyte Biotech's current ratio?
PharmaCyte Biotech had current assets of $37.4 million and current liabilities of $0.8 million, a current ratio of 45.28 (it can cover its short-term obligations).